In vivo evaluation of the role of DNp73α protein in regulating the p53-dependent apoptotic pathway after treatment with cytotoxic drugs

International Journal of Cancer

Volumn 120, Issue 3, 2007, Pages 506-513

  Sabatino, Maria Antonietta ^a   Previdi, Sara ^a   Broggini, Massimo ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Apoptosis; Colon carcinoma; DNp73 ; In vivo; p53

Indexed keywords

CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; ISOPROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN DNP73ALPHA; PROTEIN P21; PROTEIN P53; PROTEIN P53AIP1; PROTEIN P73; TETRACYCLINE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CLONE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EVALUATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR MODEL; TUMOR XENOGRAFT; WESTERN BLOTTING; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CISPLATIN; COLONIC NEOPLASMS; DNA-BINDING PROTEINS; DOXORUBICIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; NUCLEAR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33845684859     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22362     Document Type: Article

References (36)

1. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005;24:2899-908.
2. Yu J, Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 2003;331:851-8.
3. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604.
4. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
5. Lowe SW. Cancer therapy and p53. Curr Opin Oncol 1995;7:547-53.
6. Kaghad M, Bonnet H, Yang A, Creancier L, Bisean JC, Valent A, Minty A, Chalon P, Leilas JM, Dumont X, Ferrara P, McKeon F, et al. Monoalletically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-19.
7. Yang A, Kaghad M, Wang Y, Gillett B, Fleming MD, Dotsch V, Andrews NC, Caput D, McKeon F. p63, A p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998;2:305-16.
8. Irwin MS, Kaelin WG. p53 Family update: p73 and p63 develop their own identities. Cell Growth Differ 2001;12:337-49.
9. Levrero M, De Lanrenzi V, Costanzo A, Gong J, Melino G, Wang JY. Structure, function and regulation of p63 and p73. Cell Death Differ 1999;6:1146-53.
10. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 2000;113(Part 10):1661-70.
11. Harms K, Nozell S, Chen X. The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci 2004;61:822-42.
12. Melino G, De Laurenzi V, Vousden KH. p73: friend or foe in tumorigenesis. Nat Rev Cancer 2002;2:605-15.
13. Stiewe T, Putzer BM. Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Differ 2002;9:237-45.
14. Moll UM, Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res 2004;2:371-86.
15. Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S. Possible oncogenic potential of δNp73: a newly identified isoform of human p73. Cancer Res 2002;62:636-41.
16. Bourdon JC, Fernandes K, Murray-Zinijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, Lane DP. p53 Isoforms can regulate p53 transcriptional activity. Genes Dev 2005;19:2122-37.
17. Rohaly G, Chemnitz J, Dehde S, Nunez AM, Heukeshoven J, Deppert W, Dornreiter I. A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint. Cell 2005;122:21-32.
18. Grob TJ, Novak U, Maisse C, Barcaroli D, Luthi AU, Pirnia F, Hugli B, Graber HU, De Laurenzi V, Fey MF, Melino G, Tobler A. Human δ Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 2001;8:1213-23.
19. Stiewe T, Zimmermann S, Frilling A, Esche H, Pulzer BM. Transactivation-deficient δ-p73 acts as an oncogene. Cancer Res 2002;62:3598-602.
20. Stiewe T, Theseling CC, Putzer BM. Transactivation-deficient δ TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J Biol Chem 2002;277:14177-85.
21. Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, Ulmer H, Daxenbichler G, Zeimet A, Zeillinger R, Marth C, Moll UM. Transdominant {δ}TAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res 2004;64:2449-60.
22. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, Chalas E, Moll UM. δNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 2002;196:765-80.
23. Doue-Rasy S, Barrois M, Echcynne M, Kaghad M, Blanc E, Raguenez G, Goldschneider D, Terrier-Lacombe MJ, Hartmann O, Moll U, Caput D, Benard J. δN-p73α accumulates in human neuroblastic tumors. Am J Pathol 2002;160:631-9.
24. Sayan AE, Sayan BS, Findikli N, Ozturk M. Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells. Oncogene 2001;20:5111-17.
25. Casciano I, Mazzocco K, Boni L, Pagnan G, Banelli B, Allemanni G, Ponzoni M, Tonini GP, Romani M. Expression δNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 2002;9:246-51.
26. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Morita M, Funa K, Yasumoto K. Expression of δNp73 predicts poor prognosis in lung cancer. Clin Cancer Res 2004;10:6905-11.
27. Muller M, Schilling T, Sayan AE, Kairat A, Lorenz K, Schulze-Bergkamen H, Oren M, Koch A, Tannapfel A, Stremmel W, Melino G. Krammer PH. TAp73/δNp73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 2005;12:1564-77.
28. Marabese M, Marchini S, Sabatino MA, Polato F, Vikhanskaya F, Marrazzo F, Riccardi E, Scanziani E, Broggini M. Effects of inducible overexpression of DNp73|α| on cancer cell growth and response to treatment in vitro and in vivo. Cell Death Differ 2005;12:,805-14.
29. Marrazzo F, Marchini S, Previdi S, Broggini M. Questioning the oncogenic role of δNp73α in different cell lines expressing p53 or not. Carcer Biol Ther 2006;5:794-803.
30. Maisse C, Minarriz E, Barcaroli D, Melino G, De Laurenzi V. DNA damage induces the rapid and selective degradation of the δNp73 isoform allowing apoptosis to occur. Cell Death Differ 2004;11:685-7.
31. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG, Jr. Levrero M, Wang JY. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage [see comments]. Nature 1999;399:806-9.
32. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999;104:263-9.
33. Inoue T, Stuart J, Leno K, Maki CG. Nuclear import and export signals in control of the p53-related protein p73. J Biol Chem 2002;277:15053-60.
34. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002;1:639-49.
35. Matsuda K, Yoshida K, Taya Y, Nakamura K, Nakamura Y, Arakawa H. p53AIP1 regulates the mitochondrial apoptotic pathway. Cancer Res 2002;62:2883-9.
36. Yee KS, Vousden KH. Complicating the complexity of p53. Carcinogenesis 2005;26:1317-22.